SCHEMBL469971

SCHEMBL469971

COc1ccc(NC(=S)N/N=C2\C(=O)Nc3ccc([N+](=O)[O-])cc32)cc1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA12 O43570 5/20 0.49
CA1 P00915 5/20 0.49
CA2 P00918 5/20 0.49
CA9 Q16790 5/20 0.49
ALDH1A1 P00352 6/20 0.48
KDR P35968 1/20 0.47
MAPT P10636 6/20 0.47
GAA P10253 2/20 0.47
HPGD P15428 1/20 0.47
HTT P42858 1/20 0.47
SMN1; SMN2 Q16637 1/20 0.47
NPC1 O15118 2/20 0.44
PKM P14618 2/20 0.44
MEN1 O00255 1/20 0.44
HSP90AA1 P07900 1/20 0.44
KMT2A Q03164 1/20 0.44
PAX8 Q06710 1/20 0.44
NPSR1 Q6W5P4 1/20 0.44
MPI P34949 2/20 0.44
POLB P06746 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL469858 0.91 CA1 (0.54) CA12CA1CA2CA9ALDH1A1
SCHEMBL469856 0.87 ALDH1A1 (0.51) CA12CA1CA2CA9ALDH1A1
SCHEMBL457611 0.86 ALDH1A1 (0.47) CA12CA1CA2CA9ALDH1A1
SCHEMBL13061631 0.85 CA1 (0.49) CA12CA1CA2CA9ALDH1A1
SCHEMBL31492111 0.84 KDR (0.50) CA12CA1CA2CA9ALDH1A1
SCHEMBL13061642 0.84 KDR (0.50) CA12CA1CA2CA9ALDH1A1
SCHEMBL469808 0.84 KDR (0.66) CA12CA1CA2CA9ALDH1A1
SCHEMBL10085224 0.83 CA1 (0.52) CA12CA1CA2CA9ALDH1A1
SCHEMBL13008061 0.83 CA12 (0.46) CA12CA1CA2CA9ALDH1A1
SCHEMBL31491998 0.82 ALDH1A1 (0.47) ALDH1A1MAPTHPGDHTTSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2012033601-A1 THIOSEMICARBAZONES WITH MDR1 - INVERSE ACTIVITY THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH & HUMAN SERVICES (US) 2012-03-15 WO disclosed
US-20100316655-A1 COMPOUNDS WITH MDR1-INVERSE ACTIVITY INSTITUTE OF ENZYMOLOGY, BIOLOGICAL RESEARCH CENTER, HUNGARIAN ACADEMY OF SCIENCES (HU) 2010-12-16 US disclosed
WO-2009102433-A2 COMPOUNDS WITH MDR1-INVERSE ACTIVITY THE GOVERNMENT OF THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) 2009-08-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100316655-A1 COMPOUNDS WITH MDR1-INVERSE ACTIVITY ABCC1, ABCB1, ABCC2 CA12 4794/4885CA1 4780/4885CA2 4555/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.